Protein PARK2 PDB

US-based Adamas Pharmaceuticals has started a pivotal Phase III clinical trial of its most advanced wholly owned product candidate ADS-5102 (amantadine HCl) for the treatment of patients with Parkinson’s disease (PD) who have developed movement disorder levodopa-induced dyskinesia (LID).

LID is a condition characterised by involuntary movements without purpose that can become severely disabling, rendering individuals with PD unable to perform routine daily tasks.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

A total of 130 patients will be enrolled in the 26-week multi-centre, randomised, double-blind, placebo-controlled trial.

The Phase III trial (EASE LID) will assess the efficacy of a once-daily 340mg dose of ADS-5102 administered at bedtime for the treatment of LID in individuals with PD.

The trial’s primary endpoint is a reduction in LID as evaluated by changes in the unified dyskinesia rating scale (UDysRS), along with supporting data from secondary endpoints.

ADS-5102 is a high dose, controlled-release version of amantadine, that is administered once-daily at bedtime.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
"LID frequently occurs in patients after long-term treatment with levodopa, the most widely used drug for PD."

LID frequently occurs in patients after long-term treatment with levodopa, the most widely used drug for PD.

At present, there are no approved drugs for the treatment of LID in the US or Europe.

The company is also assessing ADS-5102 as a potential treatment for chronic behavioural symptoms associated with traumatic brain injury (TBI).

Parkinson’s disease causes tremors, rigidity, slowed movements and postural instability, and the most commonly prescribed treatments for this disorder are levodopa-based therapies.

Adamas’ portfolio also includes a fixed-dose combination product candidate, MDX-8704, being developed with Forest Laboratories and an approved controlled-release product Namenda XR, which Forest developed and is marketing in the US under an exclusive licence from Adamas.

Image: PDB rendering of Parkin (ligase). Photo: courtesy of Emw.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact